



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	315374	Eagle Curcuvestin Complex
ARTG entry for	Medicine Listed	
Sponsor	Integria Healthcare Australia Pty Ltd	
Postal Address	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
ARTG Start Date	13/03/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Eagle Curcuvestin Complex

Product Type	Single Medicine Product	Effective Date	11/02/2021
--------------	-------------------------	----------------	------------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support natural liver cleansing/detoxification processes
- Maintain/support general health and wellbeing
- Anti-inflammatory/relieve inflammation
- Decrease/reduce/relieve mild rheumatic aches and pains
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
 - Linked indication - Decrease/reduce/relieve mild joint aches and pains
 - Linked indication - Decrease/reduce/relieve mild joint pain/soreness
 - Linked indication - Decrease/reduce/relieve mild joint inflammation/swelling
 - Linked indication - Decrease/reduce/relieve mild joint stiffness
- Maintain/support joint health
- Maintain/support joint mobility/flexibility
- Maintain/support healthy liver function
- Maintain/support liver health

Indication Requirements

- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
- Product presentation must only refer to detoxification in relation to natural body processes.
- Product presentation must only refer to mild rheumatic aches/pains.
- Product presentation must not imply or refer to disease in any body organ, in particular the kidney or liver.
- Product presentation must only refer to mild joint symptoms.
- Product presentation must not imply or refer to drugs/alcohol.

Standard Indications



Australian Government
Department of Health
Therapeutic Goods Administration

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Acacia catechu stem heartwood Dry	50 mg
Equivalent: catechin and epicatechin (of Acacia catechu)	32.5 mg
Equivalent: Acacia catechu (Dry)	1000 mg
Curcuma longa rhizome Extract dry concentrate standardised	111 mg
Equivalent: Curcuma longa (Fresh)	18315 mg
Scutellaria baicalensis root Dry	200 mg
Equivalent: Scutellaria baicalensis (Dry)	4000 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
colloidal anhydrous silica
croscarmellose sodium
crospovidone
hypromellose
lecithin
magnesium stearate
microcrystalline cellulose
sodium starch glycollate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary